Lucid Diagnostics Inc. (LUCD)

NASDAQ: LUCD · Real-Time Price · USD
1.390
-0.130 (-8.55%)
At close: May 30, 2025, 4:00 PM
1.200
-0.190 (-13.67%)
After-hours: May 30, 2025, 7:59 PM EDT
-8.55%
Market Cap 150.38M
Revenue (ttm) 4.17M
Net Income (ttm) -70.94M
Shares Out 108.19M
EPS (ttm) -1.26
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 1,954,766
Open 1.510
Previous Close 1.520
Day's Range 1.370 - 1.530
52-Week Range 0.681 - 1.800
Beta 1.28
Analysts Strong Buy
Price Target 3.88 (+179.14%)
Earnings Date May 14, 2025

About LUCD

Lucid Diagnostics Inc. operates as a commercial-stage medical diagnostics technology company in the United States. The company focuses on patients with gastroesophageal reflux disease (GERD) who are at risk of developing esophageal precancer and cancer, primarily highly lethal esophageal adenocarcinoma. Its flagship product, the EsoGuard Esophageal DNA Test performed on samples collected with the EsoCheck Esophageal Cell collection device, a testing tool with the goal of preventing EAC deaths through early detection of esophageal precancer in a... [Read more]

Industry Medical Devices
Sector Healthcare
IPO Date Oct 14, 2021
Employees 72
Stock Exchange NASDAQ
Ticker Symbol LUCD
Full Company Profile

Financial Performance

In 2024, Lucid Diagnostics's revenue was $4.35 million, an increase of 79.00% compared to the previous year's $2.43 million. Losses were -$53.03 million, 0.68% more than in 2023.

Financial Statements

Analyst Forecast

According to 4 analysts, the average rating for LUCD stock is "Strong Buy." The 12-month stock price forecast is $3.88, which is an increase of 179.14% from the latest price.

Price Target
$3.88
(179.14% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

Lucid Diagnostics to Join Russell 2000® and Russell 3000® Indexes

NEW YORK , May 27, 2025 /PRNewswire/ -- Lucid Diagnostics Inc.  (Nasdaq: LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed I...

Other symbols: PAVM
4 days ago - PRNewsWire

PAVmed Provides Business Update and Reports First Quarter 2025 Financial Results

Lucid secured capital to extend runway well past key upcoming reimbursement milestones; ended 1Q25 with over $40 million in proforma cash Veris Health completed 1Q25 financing, resumed development of ...

Other symbols: PAVM
16 days ago - PRNewsWire

Lucid Diagnostics Inc. (LUCD) Q1 2025 Business Update Call Transcript

Lucid Diagnostics Inc. (NASDAQ:LUCD) Q1 2025 Business Update Conference Call May 14, 2025 8:30 AM ET Company Participants Matt Riley – Senior Director-Investor Relations Lishan Aklog – Chairman and C...

17 days ago - Seeking Alpha

Lucid Diagnostics Provides Business Update and Reports First Quarter 2025 Financial Results

Processed 3,034 EsoGuard® tests and recognized revenue of $0.8 million in 1Q25 Secured capital to extend runway well past key upcoming reimbursement milestones; ended 1Q25 with over $40 million in pro...

Other symbols: PAVM
17 days ago - PRNewsWire

PAVmed to Hold a Business Update Conference Call and Webcast on May 15, 2025

Conference Call and Webcast at 8:30 AM Eastern Time NEW YORK , May 1, 2025 /PRNewswire/ -- PAVmed Inc.  (Nasdaq: PAVM, PAVMZ) ("PAVmed" or the "Company"), a diversified commercial-stage medical techno...

Other symbols: PAVM
4 weeks ago - PRNewsWire

Lucid Diagnostics to Hold a Business Update Conference Call and Webcast on May 14, 2025

Conference Call and Webcast at 8:30 AM Eastern Time NEW YORK , April 30, 2025 /PRNewswire/ --  Lucid Diagnostics Inc.  (Nasdaq: LUCD) ("Lucid" or the "Company") a commercial-stage, cancer prevention m...

Other symbols: PAVM
4 weeks ago - PRNewsWire

NCI-Sponsored Study Shows Positive Data for Lucid Diagnostics' EsoGuard® Esophageal DNA Test in Patients Without Symptomatic GERD

Study supports expanded indication and market opportunity for EsoGuard esophageal precancer testing NEW YORK , April 24, 2025 /PRNewswire/ -- Lucid Diagnostics Inc.  (Nasdaq: LUCD) ("Lucid" or the "Co...

Other symbols: PAVM
5 weeks ago - PRNewsWire

Lucid Diagnostics: DNA Testing To Get Medicare Coverage, Driving Volumes, Says Bullish Analyst

According to Needham, Lucid Diagnostics Inc. LUCD is likely to receive approval for EsoGuard testing-related Medicare reimbursement, which would boost testing volumes.

7 weeks ago - Benzinga

Lucid Diagnostics Announces Closing of Public Offering of Common Stock

NEW YORK , April 11, 2025 /PRNewswire/ -- Lucid Diagnostics Inc.  (Nasdaq: LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed...

Other symbols: PAVM
7 weeks ago - PRNewsWire

Lucid Diagnostics Announces Pricing of Public Offering of Common Stock

NEW YORK , April 9, 2025 /PRNewswire/ -- Lucid Diagnostics Inc.  (Nasdaq: LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed ...

Other symbols: PAVM
7 weeks ago - PRNewsWire

Lucid Diagnostics Announces Proposed Public Offering of Common Stock

NEW YORK , April 9, 2025 /PRNewswire/ -- Lucid Diagnostics Inc.  (Nasdaq: LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed ...

Other symbols: PAVM
7 weeks ago - PRNewsWire

Lucid Diagnostics to Participate in Fireside Chat at the 24th Annual Needham Virtual Healthcare Conference

NEW YORK , April 3, 2025 /PRNewswire/ -- Lucid Diagnostics Inc.  (Nasdaq: LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company and subsidiary of PAVmed I...

Other symbols: PAVM
2 months ago - PRNewsWire

Lucid Diagnostics Launches "Embrace the Future" Campaign Showcasing EsoCheck's Groundbreaking Collect+Protect Esophageal Cell Collection Technology

Campaign will coincide with Esophageal Cancer Awareness Month and will be featured at the upcoming Digestive Disease Week (DDW) Conference NEW YORK , March 27, 2025 /PRNewswire/ -- Lucid Diagnostics I...

Other symbols: PAVM
2 months ago - PRNewsWire

Lucid Diagnostics Inc. (LUCD) Q4 2024 Earnings Call Transcript

Lucid Diagnostics Inc. (NASDAQ:LUCD) Q4 2024 Earnings Conference Call March 24, 2025 8:30 AM ET Company Participants Matt Riley - Senior Director, Investor Relations Lishan Aklog - Chairman & Chief E...

2 months ago - Seeking Alpha

Lucid Diagnostics Provides Business Update and Reports Fourth Quarter and Full Year 2024 Financial Results

Processed a record 4,042 EsoGuard tests in 4Q24, a 45% sequential and 84% annual increase Recognized EsoGuard revenue of $1.2 million in 4Q24   New sales channel generated over 20 new cash-pay concier...

Other symbols: PAVM
2 months ago - PRNewsWire

Lucid Diagnostics Announces Updated National Comprehensive Cancer Network® (NCCN) Guidelines Now Include Esophageal Precancer Screening

Highlights society guidelines recommending non-endoscopic biomarker testing, such as Lucid's EsoGuard Esophageal DNA Test, as an acceptable alternative to endoscopy NEW YORK , March 20, 2025 /PRNewswi...

Other symbols: PAVM
2 months ago - PRNewsWire

Lucid Diagnostics' ENVET-BE Clinical Utility Study of EsoGuard® Esophageal Precancer Testing Accepted for Peer-Reviewed Publication

Study confirms clinical utility of EsoGuard as a non-invasive triage tool to significantly increase positive yield of invasive upper endoscopy NEW YORK , March 18, 2025 /PRNewswire/ -- Lucid Diagnosti...

Other symbols: PAVM
2 months ago - PRNewsWire

Lucid Diagnostics Secures First Positive Commercial Insurance Coverage Policy for its EsoGuard® Esophageal DNA Test

Regional Blue Cross Blue Shield plan will cover non-invasive screening of esophageal precancer and cancer NEW YORK , March 13, 2025 /PRNewswire/ --  Lucid Diagnostics Inc.  (Nasdaq: LUCD) ("Lucid" or ...

Other symbols: PAVM
2 months ago - PRNewsWire

Lucid Diagnostics to Hold a Business Update Conference Call and Webcast on March 24, 2025

Conference Call and Webcast at 8:30 AM Eastern Time NEW YORK , March 10, 2025 /PRNewswire/ -- Lucid Diagnostics Inc.  (Nasdaq: LUCD) ("Lucid" or the "Company") a commercial-stage, cancer prevention me...

Other symbols: PAVM
2 months ago - PRNewsWire

Lucid Diagnostics Announces Closing of $15.3 Million Registered Direct Offering

NEW YORK , March 5, 2025 /PRNewswire/ --  Lucid Diagnostics Inc.  (Nasdaq: LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed...

Other symbols: PAVM
3 months ago - PRNewsWire

Lucid Diagnostics Announces $15.3 Million Registered Direct Offering

NEW YORK , March 4, 2025 /PRNewswire/ --  Lucid Diagnostics Inc.  (Nasdaq: LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed...

Other symbols: PAVM
3 months ago - PRNewsWire

Renowned Investigators Awarded $8 Million NIH Grant to Study Lucid Diagnostics' EsoGuard® in At-Risk Patients without Symptomatic GERD

Lucid to support study of this expanded indication for esophageal precancer testing in partnership with NIH investigators NEW YORK , Feb. 27, 2025 /PRNewswire/ -- Lucid Diagnostics Inc.  (Nasdaq: LUCD...

Other symbols: PAVM
3 months ago - PRNewsWire

Lucid Diagnostics Regains Compliance with Nasdaq Minimum Bid Price Requirement

NEW YORK , Feb. 25, 2025 /PRNewswire/ -- Lucid Diagnostics Inc.  (Nasdaq: LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed ...

Other symbols: PAVM
3 months ago - PRNewsWire

Lucid Diagnostics Executes First Concierge Medicine Contract with LEAA Health

LEAA Health membership-based concierge patients will now have access to EsoGuard esophageal precancer testing as part of their enhanced personalized care service on a cash-pay basis NEW YORK , Feb. 20...

Other symbols: PAVM
3 months ago - PRNewsWire

PAVmed Regains Compliance with Nasdaq Stockholders' Equity Requirement

NEW YORK , Feb. 18, 2025 /PRNewswire/ --  PAVmed Inc.  (NASDAQ: PAVM, PAVMZ) ("PAVmed" or the "Company"), a diversified commercial-stage medical technology company, operating in the medical device, di...

Other symbols: PAVM
3 months ago - PRNewsWire